IQWiG in the media

The press regularly reports on the results of IQWiG's work or asks the Institute’s researchers to comment on current developments and issues. A selection of recent articles is presented below:


The digital twin and other lucky bags of benefit assessments of drugs and non-drug interventions

In a commentary for “Observer Gesundheit”, IQWiG Director Jürgen Windeler discusses the pros and cons of randomised trials. His conclusion: Randomisation cannot be beaten.


Statutory health insurance: What do insurance funds pay and not pay for - and why?

Jürgen Windeler spoke to “Deutschlandfunk Kultur” about questions concerning which services statutory health insurance must, are supposed to, and are allowed to pay for - and who decides on this for patients and on what basis.


Drugs – the money problem

Die ZEIT cites Stefan Lange, IQWiG‘s Deputy Director “In view of the increasingly expensive treatments for rare diseases, the question arises as to how long the health care system will be able to bear the enormous costs.“


Try more evidence

Thomas Kaiser, Head of IQWiG's Drug Assessment Department, emphasizes that the European benefit assessment of drugs will not herald the end of AMNOG, the German assessment procedure.


Corona vaccination: "It's good that someone is finally writing this down so objectively!“

In an interview with RiffReporter, Klaus Koch, Head of IQWiG's Health Information Department, explains how health information considers patients' needs. (


“Questions and doubts are important“

In an interview with Cicero, IQWiG‘s Director Jürgen Windeler criticizes the lack of political interest in evidence-based medicine in the corona pandemic. (Cicero)


Rare benefit for rare diseases (

Half of orphan drugs aren’t better than the comparator treatment (

Abolish the privilege of added benefit (Tagesspiegel Background)

Fiction about the benefit of orphan drugs is “misleading” (Ärzte Zeitung)

Rare diseases: New drugs are often not better than standard treatment (

In a digital press briefing, IQWiG‘s Director Jürgen Windeler and Thomas Kaiser, Head of IQWiG's Drug Assessment Department, presented and discussed the IQWiG working paper " Evidence on Orphan Drugs". The Süddeutsche Zeitung, Deutsches Ärzteblatt, Tagesspiegel Background and Ärzte Zeitung, among others, reported in detail.


Hardly any German research on corona

In a radio interview with WDR 5 Politikum, IQWiG‘s Director Jürgen Windeler explains why scientific findings on the effects of vaccines and on measures to contain the pandemic rarely originate from Germany. (


Evidence-based information creates trust

In an article in Background Gesundheit, Klaus Koch, Head of IQWiG's Health Information Department, explains why evidence-based health information is a guarantee for building trust, also in times of a pandemic. (


Sad research culture and lack of political will

In Observer Gesundheit, IQWiG’s Director Jürgen Windeler criticizes Germany's poor contribution to clinical research, not only in the corona pandemic. (